Royalty Report: cardiac, Drugs, Biotechnology – Collection: 3533

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • cardiac
  • Drugs
  • Biotechnology
  • Disease
  • Genome
  • Stem cells
  • Therapeutic
  • Drug Discovery
  • Congestive Heart Failure
  • Medical
  • Regenerative medicine
  • Specialty

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3533

License Grant
The Licensor and the Licensee entered into an Assignment and License Agreement, pursuant to which the Licensor granted the Licensee an exclusive, worldwide license and the assignment of patents relating to certain gene therapy applications of mSCF for the treatment of cardiac ischemia. The Licensee has the right to grant sublicenses to third parties under the agreement.
License Property
Licensor owns certain intellectual property (including an issued United States patent) relating to certain gene therapy methods for delivering stem cell factor coding sequences, in order to treat certain ischemic diseases.

The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.

The Licensor intellectual property and research involves gene therapy technologies.

Field of Use
The Licensee will use the rights to gene therapy applications for the membrane bound form of Stem Cell Factor, or mSCF, for treatment of cardiac ischemia.  Cardiac ischemia occurs when blood flow to your heart muscle is decreased by a partial or complete blockage of your heart's arteries. The decrease in blood flow reduces your heart's oxygen supply and can damage your heart muscle, reducing its ability to pump efficiently.

IPSCIO Record ID: 28172

License Grant
The Licensor, a nonprofit American academic medical center, grants to the Belgium Licensee an exclusive license to make, have made, use, modify, enhance, promote, market and/or sell the Licensed Invention whether or not patented, and a non-exclusive right to use the Licensed Know-How, in the Territory within the Field of Heart Disease.
The Licensee may assigning or subcontract the rights with permission from the Licensor.
License Property
Licensed inventions means Cardiogenic Cocktail for the production of Cardiac Cells and Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure.

2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.

And the related Patents and Patent Applications;

06/592,871 Stem Cells and treatment of Vascular Tissue

06/680,775 Treating Cardiovascular Tissue

06/832,845 Methods and Materials for providing Cardiac Cells

PCT/US2005/026800 Treating Cardiovascular Tissue

PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue

PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue

PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells

3. Paragraph 2.02 is replaced with the following;

Field of Use
FIELD OF USE means cardiovascular regeneration or protection.

Field of Use means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy.

The Belgian biopharma company is involved in the discovery, development and commercialisation of regenerative and protective therapies for the treatment of cardiac diseases.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.

IPSCIO Record ID: 28042

License Grant
As part of Licensee's acquisition of the Licensor's portfolio of cardiovascular growth factor therapeutic assets, pursuant to a Technology Transfer Agreement entered into between the Licensor and the Licensee, Licensee acquired a portfolio of methods and compositions directed at the treatment of cardiovascular diseases. Licensee also has exclusive licenses to methods for introducing DNA to the heart and for improving heart muscle function, as well as to various biologics. The Licensee's resulting portfolio of cardiovascular product candidates and associated intellectual property include methods and genes applicable to the treatment of heart diseases, the promotion of healing, and the treatment of peripheral vascular disease. Among the product candidates we acquired  are Generx and Corgentin. Generx (alferminogene tadenovex) is a DNA-based, myocardial-derived growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. Angina, which is often felt as severe chest pain, can significantly limit patients’ mobility and quality of life and is a disorder that affects millions of adults in the United States and elsewhere.  In addition, we have secured the rights to Genvascor, a pre-clinical, DNA-based, endothelial nitric oxide synthase (eNOS) therapeutic.
License Property
Genvascor is being designed to induce production of nitric oxide and is directed at mediating the effects of multiple growth factors to enhance neovascularization and increased blood flow for the potential treatment of patients with critical limb ischemia due to advanced peripheral arterial occlusive disease (PAOD).
Field of Use
Licensee may elect to develop Genvascor alone or in collaboration with a development partner.

IPSCIO Record ID: 260407

License Grant
University grants to Licensee a license under Universitys interest in Patent Rights to make, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods in the Field, within the Territory and during the Term.  The amendment adds the patent information.

The licenses granted in this paragraph is exclusive with respect to the Field only.

License Property
The patent is for the therapy treatment or prevention of cardiovascular disease.
Field of Use
The Field means gene therapy for the treatment or prevention of cardiovascular diseases by the delivery of a gene or a synthetic equivalent (DNA, deoxyribonucleic acid or polydeoxyribonucleotide sequence), in whole or in part or in combination, including those encoding one or more phospholamban genes and/or SERCA-2 (sacroplasmic reticulum calcium ATPase) genes, or their mutants, excepting the involvement of anti-sense RNA (ribonucleic acid or polyribonucleotide sequence) of the phospholamban gene.

IPSCIO Record ID: 306186

License Grant
Licensor grants the Licensee of China a right and license under the Licensor IP to
(a) develop, use, demonstrate, sell, offer for sale, market, distribute, and promote Products in the Territory for use in the Field, exclusively,
(b) import Products into the Territory for use in the Field; exclusively;
(c) test and conduct independent Phase 3 clinical studies/trials on or Products in in the Territory, exclusively, and,
(d) manufacture, have manufactured, the Products solely in mainland China solely for use in the Territory and in the Field, non-exclusively.
License Property
Licensor is developing a gene therapy treatment, known as Generx.

Compound means Ad5FGF-4, alferminogene tadenovec, an angiogenic gene therapeutic, and natural evolutions thereof.

Product shall mean any biopharmaceutical product containing the Compound, alone or in combination with one or more other active pharmaceutical ingredients, in any dosage form or formulation, including any lyophilized forms thereof.

Field of Use
Field shall mean a treatment for patients with refractory angina, with myocardial ischemia, and other adverse medical conditions resulting from cardiac microvascular insufficiency.

The initial medical indication will be for the treatment of patients with refractory angina due to ischemic heart disease.

Ischemic heart disease is a condition of recurring chest pain or discomfort that occurs when a part of the heart does not receive enough blood. This condition occurs most often during exertion or excitement, when the heart requires greater blood flow.

IPSCIO Record ID: 26103

License Grant
The asset purchased with the company is a novel gene therapy through preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF).
License Property
Licensor is an early-stage biotechnology company,effectively a single-product business, fully focusing on the further development of gene therapy approaches for cardiac disease.

IPSCIO Record ID: 230517

License Grant
The Licensor granted the Kuwait Licensee the exclusive right to the intellectual property for the licensed use and development in Kuwait and other GCC/Middle East countries.
License Property
The Intellectual Property relates to methods of repairing damaged heart tissue by transplanting myoblasts that express SDF-1 and other therapeutic proteins capable of recruiting other stem cells within a patient’s own body to the cell transplant area.

The IP includes products and technologies like MyoCell for the treatment of heart damage. These are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

MyoCell is an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

Field of Use
The intent is to offer regenerative treatment options to patients, based on Licensor products and technologies like MyoCell and MyoCell SDF-1.

IPSCIO Record ID: 27156

License Grant
The Company hereby grants to InterMune the exclusive sublicense under the Genentech License Rights to develop, use, sell, offer for sale, import, make and have made Licensed Protein Products in the IG Field in the Territory.
License Property
Gene Therapy means the therapeutic or prophylactic treatment of a human being with (a) one or more oligonucleotides or nucleotide sequences.
Field of Use
IG Field means the administration to humans of Licensed Protein Product for the treatment or prevention of any human disease or condition, provided however, that IG Field shall not include (i) the administration to humans of Licensed Protein Product for the treatment or prevention of any type of arthritis or cardiac or cardiovascular disease or condition or (ii) use of Licensed Protein Product for Gene Therapy.

Gene Therapy field means the administration to humans of Licensed Gene Product for Gene Therapy for the treatment or prevention of any human disease or condition, provided however, that Gene Therapy Field shall not include any treatment or prevention of any type of cardiac or cardiovascular disease or condition.  Immunology-based products.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.